Mesoblast (MEOBF) EBITDA Margin (QoQ) (2014 - 2023)
Analysis
Mesoblast (MEOBF) EBITDA Margin (QoQ) (2014 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -16,855.00 |
| Mar 31, 2023 | 22,205.00 |
| Dec 31, 2022 | -1,451.00 |
| Sep 30, 2022 | -926,858.00 |
| Jun 30, 2022 | 909,836.00 |
| Mar 31, 2022 | -36,784.00 |
| Dec 31, 2021 | -15,451.00 |
| Sep 30, 2021 | -932,930.00 |
| Jun 30, 2021 | 1.02 Mn |
| Mar 31, 2021 | -36,768.00 |
| Dec 31, 2020 | 96,862.00 |
| Mar 31, 2020 | 93,168.00 |
| Dec 31, 2019 | -106,279.00 |
| Sep 30, 2019 | 132,539.00 |
| Jun 30, 2019 | 100,819.00 |
| Mar 31, 2019 | -79,549.00 |
| Dec 31, 2018 | -140,404.00 |
| Sep 30, 2018 | 117,046.00 |
| Jun 30, 2018 | 96,685.00 |
| Mar 31, 2018 | -226,319.00 |